Estimation of Interleukin‐10 and Interleukin‐22 Levels in the Advances of Breast Cancer
DOI:
https://doi.org/10.37506/ijfmt.v16i1.17446Keywords:
IL-10, IL-22, Breast cancer, ELISA.Abstract
Background: Breast cancer is the secant-kind of carcinoma in women with higher incidence in Iraq.
There are many prognostic and predicitive factors used for management of the breast cancer. Serum
levels of the cytokines may be utilized as a marker of immunity status and prognosis in CA breast.
Aims of the Study: Measuring the IL-10 and IL-22 in breast cancer patients and association IL-10
and IL-22 with stage and grade for breast cancer. Materials and Methods: The case-control study
was conducted on 60 women with CA. Breast and 60 controls group, patients with CA. Breast were
referred to Middle Euphrates cancer center in Najaf during the period November 2019-October 2020.
Measurement of Interleukin-10 and Interleukin-22 by using ELISA. Results: The showed a levels of
IL-10 and IL-22 in breast cancer group higher than levels of IL-10 and IL-22 in control, and showed
a high levels of IL-22 in advances stage and grade III. The showed non-significant in IL-10 levels
between four stages and three grade. Conclusions: A significant elevation levels of IL-10 and IL-22 in
breast cancer groups comparison with control, elevation significant IL-22 levels in stages and grades
of breast cancer.
Downloads
Published
Issue
Section
License
https://creativecommons.org/licenses/by-nc/2.0/deed.en